Table 2 Univariate and multivariate analyses for overall survival

AMC ≥ 530/ul

3.346 (2.178-5.141)

<0.001

1.013 (0.537-1.913)

0.976

ALC < 1120/ul

3.060 (1.878-4.988)

<0.001

1.248 (0.704-2.211)

0.448

ALC/AMC ratio < 2.0

9.482 (5.497-16.355)

<0.001

8.758 (3.917-19.581)

<0.001

LDH > normal

2.440 (1.603-3.714)

<0.001

1.092 (0.643-1.855)

0.744

KPS < 80%

2.941 (1.852-4.670)

<0.001

1.004 (0.592-1.702)

0.989

Ann Arbor stage III/IV

3.088 (1.908-4.997)

<0.001

1.061 (0.581-1.937)

0.848

ALC/AMC ratio < 3.8

5.626 (3.119-10.174)

<0.001

1.184 (0.471-2.980)

0.719

AMC ≥ 460/ul

2.864 (1.831-4.482)

<0.001

1.243 (0.696-2.220)

0.462

ALC < 1430/ul

3.017 (1.855-4.907)

<0.001

1.387 (0.765-2.513)

0.281

LDH (at diagnosis > normal)

3.061 (1.963-4.775)

<0.001

1.400 (0.818-2.398)

0.220

Time to relapse after diagnosis, months <12

7.003 (4.162-11.783)

<0.001

3.527 (1.597-7.787)

0.002

Prior rituximab treatment

0.616 (0.592-1.364)

0.899

-

-

Not ASCT

4.984 (1.819-13.655)

0.002

3.877 (1.310-11.476)

0.014